SG11201901320WA - PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS - Google Patents
PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERSInfo
- Publication number
- SG11201901320WA SG11201901320WA SG11201901320WA SG11201901320WA SG11201901320WA SG 11201901320W A SG11201901320W A SG 11201901320WA SG 11201901320W A SG11201901320W A SG 11201901320WA SG 11201901320W A SG11201901320W A SG 11201901320WA SG 11201901320W A SG11201901320W A SG 11201901320WA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- treatment
- blood cancers
- suite
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 February 2018 (22.02.2018) WIP0 I PCT Iiiimmommionotioloolllomioomomilmom oimIE (10) International Publication Number WO 2018/035446 Al (51) International Patent Classification: A61K 31/7088 (2006.01) Cl 2N 15/113 (2010.01) C07H 21/04 (2006.01) C12Q 1/68 (2006.01) (21) International Application Number: PCT/US2017/047578 (22) International Filing Date: 18 August 2017 (18.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/376,749 18 August 2016 (18.08.2016) US (71) Applicant: INTEKRIN THERAPEUTICS, INC. [US/US]; 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065 (US). (72) Inventor: MANTZOROS, Christos; 151 Coolidge Ave., #702, Watertown, MA 02472 (US). (74) Agent: POLYAKOV, Mark V. et al.; Wood, Phillips, Katz, Clark & Mortimer, 500 West Madison Street, Suite 1130, Chicago, IL 60661 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) 1-1 (54) Title: PPARy AGONIST FOR TREATMENT OF BLOOD CANCERS 71' (57) : Methods of treatment of blood cancers including leukemia and 71' 0 (1) myeloma with the compound of formula (I) known as INT131: kin 11 ,-, o ei ' ,7 \" - ci C
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662376749P | 2016-08-18 | 2016-08-18 | |
PCT/US2017/047578 WO2018035446A1 (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901320WA true SG11201901320WA (en) | 2019-03-28 |
Family
ID=61197183
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901320WA SG11201901320WA (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS |
SG10202101501PA SG10202101501PA (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10202101501PA SG10202101501PA (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210379049A1 (en) |
EP (1) | EP3500268A4 (en) |
JP (2) | JP2019524888A (en) |
KR (1) | KR20190064573A (en) |
CN (1) | CN110461329A (en) |
AU (1) | AU2017313839A1 (en) |
BR (1) | BR112019003130A2 (en) |
CA (1) | CA3034258A1 (en) |
EA (1) | EA201990512A1 (en) |
MX (1) | MX2019001979A (en) |
SG (2) | SG11201901320WA (en) |
WO (1) | WO2018035446A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016229982B2 (en) | 2015-03-09 | 2020-06-18 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
BR112019020485A2 (en) | 2017-04-03 | 2020-05-12 | Coherus Biosciences, Inc. | PPARY AGONIST FOR TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY |
WO2020243058A1 (en) * | 2019-05-30 | 2020-12-03 | Coherus Biosciences, Inc. | Compositions and methods to treat cancer |
JP2022104746A (en) * | 2020-12-29 | 2022-07-11 | 国立研究開発法人国立がん研究センター | Anticancer agent |
JP2022104747A (en) * | 2020-12-29 | 2022-07-11 | 国立研究開発法人国立がん研究センター | Antiviral agent |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3018186B1 (en) * | 1999-03-09 | 2000-03-13 | 大阪大学長 | Anti-inflammatory, monocytic cell growth inhibitor |
US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
JP2010265216A (en) * | 2009-05-14 | 2010-11-25 | Takeda Chem Ind Ltd | Heterocyclic compound |
ES2883141T3 (en) * | 2013-01-30 | 2021-12-07 | Intekrin Therapeutics Inc | PPAR-gamma agonist for the treatment of multiple sclerosis |
PT3468604T (en) * | 2016-06-08 | 2021-04-06 | Support Venture Gmbh | Pharmaceutical combinations for treating cancer |
-
2017
- 2017-08-18 KR KR1020197007705A patent/KR20190064573A/en not_active Application Discontinuation
- 2017-08-18 MX MX2019001979A patent/MX2019001979A/en unknown
- 2017-08-18 EA EA201990512A patent/EA201990512A1/en unknown
- 2017-08-18 JP JP2019530367A patent/JP2019524888A/en active Pending
- 2017-08-18 AU AU2017313839A patent/AU2017313839A1/en not_active Abandoned
- 2017-08-18 CN CN201780063382.4A patent/CN110461329A/en active Pending
- 2017-08-18 CA CA3034258A patent/CA3034258A1/en active Pending
- 2017-08-18 BR BR112019003130-8A patent/BR112019003130A2/en unknown
- 2017-08-18 SG SG11201901320WA patent/SG11201901320WA/en unknown
- 2017-08-18 EP EP17842202.8A patent/EP3500268A4/en not_active Withdrawn
- 2017-08-18 SG SG10202101501PA patent/SG10202101501PA/en unknown
- 2017-08-18 US US16/326,018 patent/US20210379049A1/en not_active Abandoned
- 2017-08-18 WO PCT/US2017/047578 patent/WO2018035446A1/en unknown
-
2022
- 2022-06-06 JP JP2022091309A patent/JP2022116304A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2019524888A (en) | 2019-09-05 |
EP3500268A4 (en) | 2020-04-15 |
CN110461329A (en) | 2019-11-15 |
JP2022116304A (en) | 2022-08-09 |
SG10202101501PA (en) | 2021-03-30 |
EP3500268A1 (en) | 2019-06-26 |
KR20190064573A (en) | 2019-06-10 |
AU2017313839A1 (en) | 2019-03-07 |
BR112019003130A2 (en) | 2019-05-21 |
EA201990512A1 (en) | 2019-08-30 |
US20210379049A1 (en) | 2021-12-09 |
WO2018035446A1 (en) | 2018-02-22 |
MX2019001979A (en) | 2019-09-19 |
CA3034258A1 (en) | 2018-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
SG11201901320WA (en) | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS | |
SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201902938TA (en) | Compounds, devices, and uses thereof | |
SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
SG11201900405XA (en) | Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia | |
SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201900043TA (en) | Antibody formulations | |
SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
SG11201408171SA (en) | Fbxo3 inhibitors |